With FDA decision near, Novartis bolsters SMA gene therapy case

Submitted by admin on April 17, 2019 - 9:57am

Source:

Biopharma Dive

News Tags:

Novartis

FDA

Zolgensma

spinal muscular atrophy

Headline:

With FDA decision near, Novartis bolsters SMA gene therapy case

snippet:

Zolgensma could be approved by the FDA within weeks. Fresh clinical data give further evidence of the therapy's benefit, although reports of two deaths may invite questions.

Search form

You are here

With FDA decision near, Novartis bolsters SMA gene therapy case

With FDA decision near, Novartis bolsters SMA gene therapy case